Petros PharmaceuticalsPTPI Pretax Margin % is % as of Mar. 2026. Among 955 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 104711.94% on this metric.
The historical rank and industry rank for Petros Pharmaceuticals's Pretax Margin % or its related term are showing as below:
PTPI's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.28 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Petros Pharmaceuticals Pretax Margin % Related Terms
Petros Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTPI vs GCAN, KOAN, PNXP: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 955 companies in the Drug Manufacturers industry.
Is Petros Pharmaceuticals' Pretax Margin % too high?
Petros Pharmaceuticals' current Pretax Margin % is %. Based on the distribution chart, Petros Pharmaceuticals ranks #999999 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Petros Pharmaceuticals' Pretax Margin % compare to GCAN and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 955 companies for Pretax Margin %. This places Petros Pharmaceuticals in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Pretax Margin % of %. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 